911±¬ÁÏÍø

In this RegMedNet interview, Professor Anna David discusses her UCL TRO supported research involving the development of new treatments for fetal growth restriction using maternal gene therapy.

With fetal growth restriction affecting 8%-10% of pregnancies and being untreatable by available drugs, Professor Anna David and team identified this as a need to try an alternative treatment, which led to them developing gene therapy for mother's to treat fetal disease. 

In this interview, Anna discusses the challenges of administering a fetal gene therapy, her experiences working with UK regulators, and next steps in her research.